SCHEMBL24257727

SCHEMBL24257727

CCOC(=O)CNC(=O)c1ncc(C(=O)c2ccccc2)c(C)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
LMNA P02545 3/20 0.47
HPGD P15428 3/20 0.46
PPID Q08752 1/20 0.43
EGLN1 Q9GZT9 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
THRA P10827 1/20 0.42
THRB P10828 1/20 0.42
TSHR P16473 1/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
ADORA3 P0DMS8 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
LTA4H P09960 1/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257550 0.87 EGLN1 (0.51) EGLN1
SCHEMBL24257569 0.81 EGLN1 (0.48) ALDH1A1HPGDPPIDEGLN1RAB9A
SCHEMBL26260136 0.80 SMN1; SMN2 (0.45) ALDH1A1LMNAHPGDPPIDEGLN1
SCHEMBL24257597 0.80 ALDH1A1 (0.47) ALDH1A1LMNAHPGDPPIDEGLN1
SCHEMBL30453015 0.80 LMNA (0.50) ALDH1A1LMNAHPGDPPIDEGLN1
SCHEMBL30546867 0.80 LMNA (0.50) ALDH1A1LMNAHPGDPPIDEGLN1
SCHEMBL24257631 0.80 PPID (0.47) ALDH1A1LMNAHPGDPPIDEGLN1
SCHEMBL24257683 0.80 LMNA (0.50) ALDH1A1LMNAHPGDPPIDEGLN1
SCHEMBL24257632 0.79 EGLN1 (0.56) ALDH1A1LMNAHPGDPPIDEGLN1
SCHEMBL24257725 0.78 ALDH1A1 (0.43) ALDH1A1LMNAHPGDPPIDEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 ALDH1A1 1362/4885LMNA 4120/4885HPGD 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.